[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639573":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":25,"overallStatus":75,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Chittagong Medical College","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin + Finerenone arm","EXPERIMENTAL","Based on the interventions, there will be two groups in the study 1. Experimental group: Dapagliflozin 10 mg plus finerenone 10 mg",[13],"Drug: Dapagliflozin +Finerenone arm",{"label":15,"type":16,"description":17,"interventionNames":18},"Dapagliflozin arm","ACTIVE_COMPARATOR","Based on the interventions, there will be two groups in the study Control group : Dapagliflozin 10 mg alone",[19],"Drug: Dapagliflozin arm",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Dapagliflozin +Finerenone arm",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Based on the interventions, there will be two groups in the study Control group : Dapagliflozin 10 mg alon",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Debasis Roy, MBBS","CONTACT","+8801737376811","debasisroy2014@gmail.com",[36],{"facility":37,"status":25,"city":38,"state":25,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Chittagong medical College hospital","Chittagong","4203","Bangladesh","BD",{"type":43,"coordinates":44},"Point",[45,46],91.83168,22.3384,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":51,"phoneExt":25,"email":52},"Mohammed Jashim Uddin, MBBS, FCPS","+8802333350180","cmc@ac.dghs.gov.bd",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Debasis Roy","MD Resident","100639573","phase-3-dapagliflozin-vs-dapagliflozin-finerenone-for-albuminuria-in-ckd-with-type-2-diabetes-100639573",false,"NCT07598864","\"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes\"","Effect of Dapagliflozin Compared to Dapagliflozin-finerenone Combination on Albuminuria in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Randomized Controlled Trial.","Inclusion criteria:\n\nPatients aged ≥ 18 years Patients with T2 DM , as defined by the American Diabetic Association. Urinary ACR ≥ 30 mg\u002Fg and eGFR ≥ 25 ml\u002Fmin per 1.73 m2 Prior treatment with ACEIs or ARBs for more than four weeks up to the maximum tolerated dose Serum potassium ≤ 4.8 mmol\u002FL\n\nExclusion criteria\n\n* Patients with other known causes of proteinuria, e.g. UTI, fever\n* At screening visit SBP higher than 160 mmHg or DBP higher than 100 mmHg or SBP lower than 90 mmHg\n* Glycated hemoglobin (HbA1C) \\>11%\n* Known hypersensitivity to dapagliflozin or finerenone\n* Known case of Addison's disease\n* Known case of hepatic insufficiency\n* Treatment with SGLT2i (empagliflozin:62 hours, dapagliflozin:65hours) or MRAs (finerenone:10-20 hours, spironolactone:7 hours , eplerenone:15-30 hours) within their wash out periods.\n* Patients on non-dihydropyridine Calcium Chanel blockers or Glucagon-like peptide-1 (GLP-1) agonists\n* Pregnant lady or lactating mother","ALL","18 Years",{"count":67,"type":68},88,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is a major cause of morbidity, commonly associated with persistent albuminuria and progressive renal decline. Reducing albuminuria is a key therapeutic goal to slow disease progression. Sodium-glucose cotransporter-2 inhibitors like dapagliflozin and non-steroidal mineralocorticoid receptor antagonists such as finerenone have independently shown significant renoprotective effects. Their combined use may provide additive benefits.\n\nThis open-label randomized controlled trial will be conducted in the Department of Nephrology, Chittagong Medical College Hospital, Bangladesh, including 88 patients with CKD and T2DM. Participants will be randomized into two groups: one receiving dapagliflozin 10 mg plus finerenone 10 mg daily, and the other receiving dapagliflozin 10 mg alone for eight weeks.\n\nThe primary outcome will be the change in urinary albumin-to-creatinine ratio (UACR). Secondary outcomes include serum creatinine, estimated glomerular filtration rate (eGFR), and serum potassium. Safety and adverse events will also be monitored. Data will be analyzed using SPSS version 27.\n\nThis study aims to assess whether combination therapy is more effective than dapagliflozin alone in reducing albuminuria and may help guide treatment strategies in diabetic CKD.",[74],"Diabetic Nephropathy","NOT_YET_RECRUITING","2026-05-14",{"date":78,"type":79},"2026-05-20","ACTUAL",{"date":81,"type":68},"2026-05-01",{"date":83,"type":68},"2027-05-01",{"name":5,"class":6},1]